Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Tapestry, Inc. (TPR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Tapestry, Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.78 (market cap $29.60B), while Tapestry, Inc. trades at $153.24 (market cap $32.44B). The key difference: Alnylam Pharmaceuticals, Inc. and Tapestry, Inc. are close in size by market cap, and Tapestry, Inc. pays a 1% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | TPR | |
|---|---|---|
Market Cap | $29.60B | $32.44B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $164.78 |
52-Week Low | $205.48 | $95.69 |
Enterprise Value | $27.56B | $35.29B |
Dividend Yield | — | 1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.
The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.
TPR trades at $153.17, down 7.05% over 24 hours, with a bullish technical signal from moving averages and strong analyst consensus. The company reported Q1 2026 EPS of $1.66, beating expectations of $1.30, and maintains robust profitability with a gross margin of 76.18% and ROE of 55.74%. Recent news highlights AI integration efforts and upcoming Q4 earnings on August 13, 2026.
Outlook is positive driven by earnings beats and brand momentum, but risks include high valuation multiples and debt levels. The consensus price target is $190.33, implying significant upside, supported by 75.61% buy ratings from analysts. Investors should monitor Q2 2026 earnings and debt management for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Tapestry, Inc.
Coach, Kate Spade, and Stuart Weitzman are the fashion and accessory brands that comprise Tapestry. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (67% of fiscal 2022 sales), Europe, Asia (28% of fiscal 2022 sales), and elsewhere. Coach (74% of fiscal 2022 sales) is best known for affordable luxury leather products. Kate Spade (22% of fiscal 2022 sales) is known for colorful patterns and graphics. Women's handbags and accessories produced 69% of Tapestry's sales in fiscal 2022. Stuart Weitzman, Tapestry's smallest brand, generates nearly all its revenue from women's footwear.
Read more on TPR →
